SCHEMBL4404222

SCHEMBL4404222

CN(C)C(=O)c1ccc(C(C)(C)C)cc1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.47
▸ CYP2C19 P33261 1/20 0.45
▸ PDK2 Q15119 2/20 0.43
▸ HSP90AA1 P07900 1/20 0.43
▸ HSP90AB1 P08238 1/20 0.43
▸ FLT1 P17948 1/20 0.43
▸ FLT4 P35916 1/20 0.43
▸ KDR P35968 1/20 0.43
▸ NR1H4 Q96RI1 2/20 0.42
▸ HPGD P15428 2/20 0.41
▸ AKR1C2 P52895 1/20 0.41
▸ AKR1C1 Q04828 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ ESRRB O95718 1/20 0.41
▸ ESRRG P62508 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ NPC1 O15118 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ EPHX2 P34913 1/20 0.40
▸ RXRA P19793 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4404284 0.82 TDP1 (0.46) ALDH1A1HSP90AA1HSP90AB1NR1H4HPGD
SCHEMBL27593550 0.82 CYP2C19 (0.50) ALDH1A1CYP2C19HSP90AA1HSP90AB1FLT1
SCHEMBL14092989 0.81 ALDH1A1 (0.52) ALDH1A1PDK2HSP90AA1HSP90AB1NR1H4
SCHEMBL4852678 0.80 NR1H4 (0.58) ALDH1A1CYP2C19FLT1FLT4KDR
SCHEMBL11342078 0.80 CYP2C19 (0.49) ALDH1A1CYP2C19HSP90AA1HSP90AB1FLT1
SCHEMBL4402382 0.79 SMN1; SMN2 (0.49) ALDH1A1PDK2HSP90AA1HSP90AB1NR1H4
SCHEMBL4403995 0.79 HSP90AA1 (0.43) ALDH1A1CYP2C19HSP90AA1HSP90AB1NR1H4
SCHEMBL10331377 0.79 ATR (0.47) ALDH1A1CYP2C19PDK2HPGDAKR1C2
SCHEMBL4866162 0.79 KMT2A (0.49) ALDH1A1CYP2C19FLT1FLT4KDR
SCHEMBL9653150 0.78 ALDH1A1 (0.60) ALDH1A1HPGDHTTTDP1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150353495-A1 NICOTINAMIDES AS JAK KINASE MODULATORS ALEXION PHARMACEUTICALS, INC. 2015-12-10 — — US disclosed
US-9102625-B2 Nicotinamides as JAK kinase modulators PORTOLA PHARMACEUTICALS, INC. (US) 2015-08-11 — — US disclosed
US-20120108566-A1 NICOTINAMIDES AS JAK KINASE MODULATORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-05-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353495-A1 NICOTINAMIDES AS JAK KINASE MODULATORS JAK2, JAK1, NADK ALDH1A1 780/4885CYP2C19 253/4885PDK2 210/4885
US-20120108566-A1 NICOTINAMIDES AS JAK KINASE MODULATORS JAK2, JAK1, NADK ALDH1A1 780/4885CYP2C19 253/4885PDK2 210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback